Simufilam’s suppression of the elevated basal CCR5–G protein coupling and improvement to CCR5’s responsivity to its ligand CCL3 again support the hypothesis that simufilam reduces chronic activation of multiple inflammatory receptors in AD. Here, CCL3 is linked to Alzheimer disease.